Teva: Amgen’s Interchangeable Humira Biosimilar Too Late For January 2023
Israeli Firm Commits To Debt Repayment And Rules Out High-Cash Deals
Teva discussed its proposed rivals in the US biosimilar adalimumab space, biosimilar business development plans and prioritizing debt during its Q3 earnings call. The Israeli firm’s revenues succumbed to challenges in the US generics space.
